U.S. markets close in 7 minutes
  • S&P 500

    4,226.25
    -20.34 (-0.48%)
     
  • Dow 30

    34,056.03
    -243.30 (-0.71%)
     
  • Nasdaq

    14,048.65
    -24.20 (-0.17%)
     
  • Russell 2000

    2,313.35
    -6.72 (-0.29%)
     
  • Crude Oil

    71.93
    -0.19 (-0.26%)
     
  • Gold

    1,835.60
    -20.80 (-1.12%)
     
  • Silver

    27.52
    -0.17 (-0.61%)
     
  • EUR/USD

    1.2012
    -0.0121 (-1.00%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • GBP/USD

    1.3999
    -0.0083 (-0.59%)
     
  • USD/JPY

    110.5870
    +0.5530 (+0.50%)
     
  • BTC-USD

    38,752.13
    -1,287.55 (-3.22%)
     
  • CMC Crypto 200

    962.91
    -29.56 (-2.98%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

ESSA Pharma's Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • ESSA Pharma Inc (NASDAQ: EPIX) has announced initial data from Phase 1 trial evaluating the company's lead candidate, EPI-7386, to treat patients with metastatic castration-resistant prostate cancer. Data were at the 2021 American Society of Clinical Oncology Genitourinary

  • Data highlights compare preclinical projections of EPI-7386's clinical pharmacokinetic parameters to the pharmacokinetic, safety, and preliminary clinical data from the initial 200 mg cohort in patients who progressed on two or more approved systemic therapies.

  • In this initial cohort, EPI-7386 was well-tolerated with no severe adverse events observed.

  • EPI-7386 was well-absorbed, demonstrated high exposure levels, and was confirmed to have a long half-life of at least 24 hours. The predicted exposures of EPI-7386 in patients were similar to modeled projections and were still below optimal target exposures of EPI-7386 associated with anti-tumor activity in animal models.

  • One out of three patients who completed 12 weeks of therapy experienced a prostate-specific antigen decline (PSA) of more than 50% after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through six cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate.

  • ESSA recently completed the 28-Day safety evaluation period for the 400mg dose cohort and is currently dosing patients in the 600 mg cohort.

  • More clinical data is expected in the second half of 2021.

  • Price Action: EPIX stock gained 46% at $28.29 during market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.